BRISBANE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will hold a press conference* at 4:00 PM Pacific Time on June 5th, 2018 in the Sheraton Seattle Hotel, Ballard Room to highlight new AlloSure data at the 2018 American Transplant Congress.
Peter Maag, CareDx President and Chief Executive Officer and Daniel C. Brennan, M.D., Medical Director, Comprehensive Transplant Center - Johns Hopkins Medical Center will be presenting during the press conference and will be available for a Q&A session. A live webcast of the press conference will be available at the following link http://public.viavid.com/index.php?id=129745.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.
For more information, please visit: www.CareDx.com.
*This press conference is not part of the ATC official educational program
CONTACTS:
CareDx, Inc.
Sasha King
Chief Commercial Officer
+1 415-287-2393
sking@caredx.com
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
+1 646-277-1266
david.clair@icrinc.com